Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q1- Text added to 2020 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
ACTEMRA, adult, AG, analgesia, analog, antiviral, arbitrage, binding, canakinumab, clearance, combating, conflict, cough, crucial, cytokine, daily, developmental, dexamethasone, dissipate, EC, Eli, Emergency, enhance, enzyme, ethnic, evidenced, expertise, fixation, Genentech, Gilead, hallmark, hydrogen, Importantly, impurity, Incyte, infection, inflammatory, justify, Lilly, longevity, lung, main, mediated, mortality, neurogenic, nucleotide, osteotomy, passed, plasma, protease, racial, rationale, remdesivir, reproductive, respiratory, ruxolitinib, screening, somatic, step, storm, Suppressing, syndrome, task, threat, tie, tocilizumab, tradipitant, unpredictable, Vanda, ventilation, worldwide, ZYNRELEF
Removed:
anticipation, ascertainable, collectability, formal, half, performed, shortened
Valuein 2020 Q1 filing- Value in 2020 Q2 filing
Original filings
Filing view